American Century Companies Inc. Has $11.17 Million Position in Emergent Biosolutions Inc. $EBS

Key Points

• American Century Companies Inc. increased its stake in Emergent Biosolutions Inc. by 7.5% in the first quarter, acquiring an additional 159,909 shares to own a total of 2,297,621 shares valued at approximately $11.17 million.
• Emergent Biosolutions' shares have experienced a decrease, with the stock trading down 5.4% recently, opening at $8.70, encountering a fifty-two week low of $4.02 and a high of $12.73.
• Analyst ratings for Emergent Biosolutions were adjusted, with Wall Street Zen downgrading the stock from a "buy" to a "hold" rating, while three analysts still maintain a "buy" rating, reflecting mixed investor sentiment.

American Century Companies Inc. increased its stake in Emergent Biosolutions Inc. (NYSE:EBS - Free Report) by 7.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,297,621 shares of the biopharmaceutical company's stock after buying an additional 159,909 shares during the period. American Century Companies Inc. owned about 4.23% of Emergent Biosolutions worth $11,166,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in EBS. Fox Run Management L.L.C. acquired a new stake in Emergent Biosolutions during the first quarter valued at approximately $136,000. Russell Investments Group Ltd. increased its holdings in shares of Emergent Biosolutions by 27,025.6% in the 1st quarter. Russell Investments Group Ltd. now owns 158,685 shares of the biopharmaceutical company's stock valued at $771,000 after acquiring an additional 158,100 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Emergent Biosolutions by 3.2% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 931,627 shares of the biopharmaceutical company's stock valued at $4,528,000 after acquiring an additional 29,295 shares in the last quarter. Alberta Investment Management Corp bought a new position in Emergent Biosolutions during the first quarter worth $458,000. Finally, XTX Topco Ltd acquired a new position in Emergent Biosolutions in the first quarter worth $417,000. 78.40% of the stock is currently owned by institutional investors.

Emergent Biosolutions Stock Performance

Shares of Emergent Biosolutions stock traded down $0.11 during trading on Monday, hitting $8.29. 898,751 shares of the stock were exchanged, compared to its average volume of 1,406,032. The company has a debt-to-equity ratio of 1.25, a quick ratio of 3.00 and a current ratio of 5.66. Emergent Biosolutions Inc. has a 12 month low of $4.02 and a 12 month high of $12.73. The stock's fifty day moving average is $7.46 and its 200 day moving average is $6.44. The stock has a market cap of $442.00 million, a PE ratio of 3.38 and a beta of 2.03.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.42. Emergent Biosolutions had a return on equity of 24.63% and a net margin of 16.38%.The business had revenue of $140.90 million during the quarter, compared to the consensus estimate of $148.55 million. As a group, sell-side analysts anticipate that Emergent Biosolutions Inc. will post -0.63 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded shares of Emergent Biosolutions from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $14.33.

Insider Buying and Selling

In other Emergent Biosolutions news, Director Donald W. Degolyer sold 7,844 shares of the stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $8.65, for a total transaction of $67,850.60. Following the completion of the transaction, the director directly owned 137,659 shares of the company's stock, valued at approximately $1,190,750.35. This trade represents a 5.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kathryn C. Zoon sold 7,086 shares of the firm's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $8.87, for a total transaction of $62,852.82. Following the transaction, the director owned 71,799 shares of the company's stock, valued at approximately $636,857.13. This trade represents a 8.98% decrease in their position. The disclosure for this sale can be found here. 3.20% of the stock is owned by company insiders.

Emergent Biosolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.